연구동향 분석
박사

천연물에서 유래한 Tyrosine kinase 저해제 발굴과 항암 기전에 관한 연구 = A study on the identification of tyrosine kinase inhibitors and investigation of their anti-cancer mechanisms

오하나 2020년

논문상세정보
인용/피인용
' 천연물에서 유래한 Tyrosine kinase 저해제 발굴과 항암 기전에 관한 연구 = A study on the identification of tyrosine kinase inhibitors and investigation of their anti-cancer mechanisms' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Echinatin
  • Janus kinase 2
  • Licochalcone
  • Oral squamous cell carcinoma
  • Tyrosine kinases
  • apopto-sis
  • c-met
  • epidermalgrowthfactorreceptor
  • nonsmallcelllungcarcinoma
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
752 0

0.0%

' 천연물에서 유래한 Tyrosine kinase 저해제 발굴과 항암 기전에 관한 연구 = A study on the identification of tyrosine kinase inhibitors and investigation of their anti-cancer mechanisms' 의 참고문헌

  • YAMAOKA, T., KUSUMOTO, S., ANDO, K., OHBA, M. & OHMORI, T. 2018. Receptor Tyrosine Kinase-Targeted Cancer Therapy. Int J Mol Sci, 19. YANG, S. F., YANG, W. E., CHANG, H. R., CHU, S. C. & HSIEH, Y. S. 2008.
    [2008]
  • Virtual screening of natural compounds as inhibitors of EGFR 696-1022 T790M associated with non-small cell lung cancer
    12 , 311 . [2016]
  • Trends in the incidence of and survival rates for oral cavity cancer in the Korean population
    20 , 773-9 . [2014]
  • Toxicological Effects of Glycyrrhiza glabra ( Licorice ) : A Review
    31 , 1635-1650 . [2017]
  • Therapeutic potential of JAK2 inhibitors
    [2009]
  • TheCellCycle : a review of regulation , deregulation and therapeutic targets inCancer
    36 , 131-49 . [2003]
  • The role of erlotinib ( Tarceva , OSI 774 ) in the treatment of non-small cell lung cancer . Clin Cancer Res , 10 , 4238s4240s . PFEFFER , C. M. & SINGH , A. T. K. 2018 . Apoptosis : A Target for Anticancer Therapy
    19 [2004]
  • The role of JAK/STAT signalling in the pathogenesis , prognosis and treatment of solid tumours
    113 , 365-71 [2015]
  • The protein tyrosine kinase family of the human genome
    19 , 5548-57 [2000]
  • The changing face of head and neck cancer in the 21st century : the impact of HPV on the epidemiology and pathology of oral cancer
    3 , 78-81 [2009]
  • The ErbB/HER family of protein-tyrosine kinases and cancer
    79 , 34-74 [2014]
  • The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro
    17 , 545-555 [2017]
  • Ten things you should know about protein kinases : IUPHAR Review 14
    172 , 2675-2700 [2015]
  • Targeting the STAT3 signaling pathway in cancer : role of synthetic and natural inhibitors
    [2014]
  • Targeting apoptosis pathways in cancer by Chinese medicine
    332 , 304-12 [2013]
  • Targeted cancer therapy
    [2004]
  • THATCHER, N., CHANG, A., PARIKH, P., RODRIGUES PEREIRA, J., CIULEANU, T., VON PAWEL, J., THONGPRASERT, S., TAN, E. H., PEMBERTON, K., ARCHER, V. & CARROLL, K. 2005. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366, 1527-37.
  • TANG, Z., DU, R., JIANG, S., WU, C., BARKAUSKAS, D. S., RICHEY, J., MOLTER, J., LAM, M., FLASK, C., GERSON, S., DOWLATI, A., LIU, L., LEE, Z., HALMOS, B., WANG, Y., KERN, J. A. & MA, P. C. 2008. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer, 99, 911-22.
  • Systemic chemotherapy for advanced non-small cell lung cancer : recent advances and future directions
    13 Suppl 1 , 5-13 [2008]
  • Symptoms in adults with lung cancer . A systematic research review
    19 , 137-53 [2000]
  • Screening of hepatoprotectiveCompounds from licorice againstCarbon tetrachloride and acetaminophen induced HepG2Cells injury
    34 , 59-66 . [2017]
  • STATs in oncogenesis
    19 , 2474-88 . [2000]
  • STAT3-mediated transcription of Bcl-2 , Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells
    392 , 335-44 [2005]
  • SORIA, J. C., OHE, Y., VANSTEENKISTE, J., REUNGWETWATTANA, T., CHEWASKULYONG, B., LEE, K. H., DECHAPHUNKUL, A., IMAMURA, F., NOGAMI, N., KURATA, T., OKAMOTO, I., ZHOU, C., CHO, B. C., CHENG, Y., CHO, E. K., VOON, P. J., PLANCHARD, D., SU, W. C., GRAY, J. E., LEE, S. M., HODGE, R., MAROTTI, M., RUKAZENKOV, Y., RAMALINGAM, S. S. & INVESTIGATORS, F. 2018. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med, 378, 113-125.
  • SILVENNOINEN , O . 2011 . The pseudokinase domain of JAK2 is a dualspecificity protein
    . Nat Struct
  • SHI, P., OH, Y. T., ZHANG, G., YAO, W., YUE, P., LI, Y., KANTETI, R., RIEHM, J., SALGIA, R., OWONIKOKO, T. K., RAMALINGAM, S. S., CHEN, M. & SUN, S. Y. 2016. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett, 380, 494-504.
  • S. N. 2018 . Phytochemicals , withaferin A andCarnosol , overcome pancreaticCancer stemCells asC-Met inhibitors
    106 , 1527-1536 .
  • S. H. 2013b . Short and efficient synthesis of licochalcone B and D through acidmediatedClaisen-SchmidtCondensation
    34 , 3906-3908 .
  • S. H. 2013a .Concise synthesis of licochalconeC and its regioisomer
    36 , 1432-6 .
  • Role of the hepatocyte growth factor receptor ,C-Met , in oncogenesis and potential for therapeutic inhibition
    13 , 41-59
  • Role of reactive oxygen species ( ROS ) in apoptosis induction
    5 , 415-8 [2000]
  • Role of licochalconeC inCardioprotection against ischemia/reperfusion injury of isolated rat heart via antioxidant , anti-inflammatory , and antiapoptotic activities
    132 , 27-33 [2015]
  • Resistance mechanisms to osimertinib in EGFRmutated non-smallCell lungCancer .
    121 , 725-737 . [2019]
  • Reactive oxygen species ,Cellular redox systems , and apoptosis
    48 , 749-62 [2010]
  • Rational , biologically based treatment of EGFR-mutant non-small-cell lungCancer
    10 , 760-74 . [2010]
  • RIELY, G. J., PAO, W., PHAM, D., LI, A. R., RIZVI, N., VENKATRAMAN, E. S., ZAKOWSKI, M. F., KRIS, M. G., LADANYI, M. & MILLER, V. A. 2006. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res, 12, 839-44.
  • Quantitative analysis of dose-effect relationships : theCombined effects of multiple drugs or enzyme inhibitors
    22 , 27-55 [1984]
  • QUINTANAL-VILLALONGA, A., PAZ-ARES, L., FERRER, I. & MOLINAPINELO, S. 2016. Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications. Dis Markers, 2016, 9214056.
  • ProgrammedCell death pathways inCancer : a review of apoptosis , autophagy and programmed necrosis
    45 , 487-98 . [2012]
  • Prediction ofCancer Incidence and Mortality in Korea , 2019
    51 , 431-437 . [2019]
  • Potential therapeutic targets for oralCancer : ADM , TP53 , EGFR , LYN ,CTLA4 , SKIL ,CTGF ,CD70
    9 , e102610 . [2014]
  • Potential proapoptotic phytochemical agents for the treatment and prevention ofColorectalCancer
    18 , 487-498 [2019]
  • Platinum-based versus non-platinum-basedChemotherapy in advanced non-small-cell lungCancer : a meta-analysis of the published literature
    23 , 2926-36 [2005]
  • Plants vs.Cancer : a review on natural phytochemicals in preventing and treatingCancers and their druggability
    12 , 1281-305
  • Plant derived substances with anti-cancer activity : from folklore to practice
    6 , 799 . [2015]
  • Plant derived anticancer agents : A green approach towards skinCancers
    103 , 1643-1651 . [2018]
  • Phosphorylated EGFR expression may predict outcome of EGFR-TKI therapy for the advanced NSCLC patients with wild-type EGFR
    31 , 65 .
  • Pharmacological Targeting of Cell Cycle , Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells
    19
  • Particulate Matter Exposure : Genomic Instability , Disease , and Cancer Risk
    [2019]
  • PURI, N. & SALGIA, R. 2008. Synergism of EGFR and c-Met pathways, crosstalk and inhibition, in non-small cell lung cancer. J Carcinog, 7, 9. QIU, C., ZHANG, T., ZHANG, W., ZHOU, L., YU, B., WANG, W., YANG, Z., LIU, Z., ZOU, P. & LIANG, G. 2017. Licochalcone A inhibits the proliferation of human lung cancer cell lines A549 and H460 by inducing G2/M cell cycle arrest and er stress. Int J Mol Sci, 18, 1761.
  • PARK, K., TAN, E. H., O'BYRNE, K., ZHANG, L., BOYER, M., MOK, T., HIRSH, V., YANG, J. C., LEE, K. H., LU, S., SHI, Y., KIM, S. W., LASKIN, J., KIM, D. W., ARVIS, C. D., KOLBECK, K., LAURIE, S. A., TSAI, C. M., SHAHIDI, M., KIM, M., MASSEY, D., ZAZULINA, V. & PAZ-ARES, L. 2016. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol, 17, 577-89.
  • P. P. 2004 . Jak2 tyrosine kinase : a true jak of all trades ?
    41 , 207-32 .
  • Oxidative and antioxidative mechanisms in oral cancer and precancer : a review
    50 , 10-8 [2014]
  • Oral squamous cell carcinoma : review of prognostic and predictive factors
    102 , 67-76 [2006]
  • Oral cavity and oropharyngeal squamous cell carcinoma-an update .
    65 , 401-21 [2015]
  • OH, H., YOON, G., SHIN, J. C., PARK, S. M., CHO, S. S., CHO, J. H., LEE, M. H., LIU, K., CHO, Y. S., CHAE, J. I. & SHIM, J. H. 2016. Licochalcone B induces apoptosis of human oral squamous cell carcinoma through the extrinsic- and intrinsic-signaling pathways. Int J Oncol, 48, 1749-57.
  • Non-small cell lung cancer : current treatment and future advances
    5 , 288-300 . [2016]
  • Natural Compound Licochalcone B Induced Extrinsic and Intrinsic Apoptosis in Human Skin Melanoma ( A375 ) and Squamous Cell Carcinoma ( A431 ) Cells
    31 , 1858-1867 . [2017]
  • NEAL, J. W., DAHLBERG, S. E., WAKELEE, H. A., AISNER, S. C., BOWDEN, M., HUANG, Y., CARBONE, D. P., GERSTNER, G. J., LERNER, R. E., RUBIN, J. L., OWONIKOKO, T. K., STELLA, P. J., STEEN, P. D., KHALID, A. A., RAMALINGAM, S. S. & INVESTIGATORS, E.-A. 2016. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol, 17, 1661-1671.
  • Molecularlytargeted therapy for the oral cancer stem cells
    54 , 88-103 [2018]
  • Molecular pathways : Jak/STAT pathway : mutations , inhibitors , and resistance
    19 , 1933-40 [2013]
  • Molecular biomarkers for lung adenocarcinoma
    49 [2017]
  • Modulation of death receptors by cancer therapeutic agents
    7 , 163-173 [2008]
  • Mitochondrial control of cell death
    6 , 513-9 . [2000]
  • Mechanisms of resistance to EGFR tyrosine kinase inhibitors
    5 , 390-401 . [2015]
  • Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer
    165214 [2011]
  • Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer
    14 , 2895-9 . [2008]
  • Mechanisms for oncogenic activation of the epidermal growth factor receptor .
    19 , 2013-23 . [2007]
  • MOK, T. S., WU, Y. L., THONGPRASERT, S., YANG, C. H., CHU, D. T., SAIJO, N., SUNPAWERAVONG, P., HAN, B., MARGONO, B., ICHINOSE, Y., NISHIWAKI, Y., OHE, Y., YANG, J. J., CHEWASKULYONG, B., JIANG, H., DUFFIELD, E. L., WATKINS, C. L., ARMOUR, A. A. & FUKUOKA, M. 2009. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57.
  • MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
    12 , 63
  • MAEMONDO, M., INOUE, A., KOBAYASHI, K., SUGAWARA, S., OIZUMI, S., ISOBE, H., GEMMA, A., HARADA, M., YOSHIZAWA, H., KINOSHITA, I., FUJITA, Y., OKINAGA, S., HIRANO, H., YOSHIMORI, K., HARADA, T., OGURA, T., ANDO, M., MIYAZAWA, H., TANAKA, T., SAIJO, Y., HAGIWARA, K., MORITA, S., NUKIWA, T. & NORTH-EAST JAPAN STUDY, G. 2010. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 362, 2380-8.
  • M. & SIEGFRIED , J. M. 2018 . Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer . Cancers ( Basel ) , 10 . MO , H. N. & LIU , P. 2017 . Targeting MET in cancer therapy
    3 , 148-153 .
  • Luteolin induces apoptosis in oral squamous cancer cells. J Dent Res, 87, 401-6.
  • Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival
    67 , 2081-8 [2007]
  • Licorice ( Glycyrrhiza glabra Linn . ) oils . Essential Oils in Food Preservation , Flavor and Safety
    [2016]
  • Licochalcone C induces apoptosis via B-cell lymphoma 2 family proteins in T24 cells
    12 , 7623-8 [2015]
  • Licochalcone B inhibits growth of bladder cancer cells by arresting cell cycle progression and inducing apoptosis
    65 , 242-51 [2014]
  • Licochalcone B Extracted from Glycyrrhiza uralensis Fisch Induces Apoptotic Effects in Human Hepatoma Cell HepG2
    67 , 3341-3353
  • Licochalcone B Arrests Cell Cycle Progression and Induces Apoptosis in Human Breast Cancer MCF-7 Cells
    11 , 444-452 . [2016]
  • Licocalchone-C extracted from Glycyrrhiza glabra inhibits lipopolysaccharide-interferon-gamma inflammation by improving antioxidant conditions and regulating inducible nitric oxide synthase expression
    16 , 5720-34 .
  • LIN, H. Y., HOU, S. C., CHEN, S. C., KAO, M. C., YU, C. C., FUNAYAMA, S., HO, C. T. & WAY, T. D. 2012. (-)-Epigallocatechin gallate induces Fas/CD95-mediated apoptosis through inhibiting constitutive and IL-6- induced JAK/STAT3 signaling in head and neck squamous cell carcinoma cells. J Agric Food Chem, 60, 2480-9.
  • LI, Y., WANG, Y., NIU, K., CHEN, X., XIA, L., LU, D., KONG, R., CHEN, Z., DUAN, Y. & SUN, J. 2016. Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation. Oncotarget, 7, 70535-70545.
  • LEIGHL, N. B., TSAO, M. S., LIU, G., TU, D., HO, C., SHEPHERD, F. A., MURRAY, N., GOFFIN, J. R., NICHOLAS, G., SAKASHITA, S., CHEN, Z., KIM, L., POWERS, J., SEYMOUR, L., GOSS, G. & BRADBURY, P. A. 2017. A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. Oncotarget, 8, 69651-69662.
  • LBA51 Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study .
    29 , mdy424 . 064 .
  • Kaempferol and quercetin , components of Ginkgo biloba extract ( EGb 761 ) , induce caspase-3-dependent apoptosis in oral cavity cancer cells
    24 Suppl 1 , S77-82 . [2010]
  • JUNG, S. K., LEE, M. H., LIM, D. Y., LEE, S. Y., JEONG, C. H., KIM, J. E., LIM, T. G., CHEN, H., BODE, A. M., LEE, H. J., LEE, K. W. & DONG, Z. 2015. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinibresistant lung cancer growth. Mol Carcinog, 54, 322-31.
  • JI, S., LI, Z., SONG, W., WANG, Y., LIANG, W., LI, K., TANG, S., WANG, Q., QIAO, X., ZHOU, D., YU, S. & YE, M. 2016. Bioactive Constituents of Glycyrrhiza uralensis (Licorice): Discovery of the Effective Components of a Traditional Herbal Medicine. J Nat Prod, 79, 281-92.
  • JAK2 inhibitors for myeloproliferative neoplasms : what is next ?
    130 , 115-125 [2017]
  • JAK family of kinases in cancer
    22 , 423-34 . [2003]
  • J. R. 2015 . JAK kinase inhibition abrogates STAT3 activation and head and neck squamous
    growth . Neoplasia , [2015]
  • J. , PREISS , J. H. , VAN DEN WEYNGAERT , D. , AWADA , A. , CUPISSOL , D. , KIENZER
    A. , DESAUNOIS ,
  • Honokiol , a natural product , overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor ,
    [2019]
  • High MET amplification level as a resistance mechanism to osimertinib ( AZD9291 ) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression
    98 , 59-61 [2016]
  • Hepatoprotective effects of licochalcone B on carbon tetrachloride-induced liver toxicity in mice
    19 , 910-915 [2016]
  • HUANG, J. S., YAO, C. J., CHUANG, S. E., YEH, C. T., LEE, L. M., CHEN, R. M., CHAO, W. J., WHANG-PENG, J. & LAI, G. M. 2016. Honokiol inhibits sphere formation and xenograft growth of oral cancer side population cells accompanied with JAK/STAT signaling pathway suppression and apoptosis induction. BMC Cancer, 16, 245.
  • H. 2012. cMET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas .
    7 , 331-9 .
  • GUERRA , B . & FERNãNDEZPëREZ , L. 2019 . JAK , an Oncokinase in Hematological Cancer . Function of Tyrosine Kinases and Related Network in Cancer . IntechOpen . REDZA-DUTORDOIR , M. & AVERILL-BATES , D. A . 2016
    pathways by reactive [2019]
  • GRP78 expression beyond cellular stress : A biomarker for tumor manipulation
    5 , 78-85 [2015]
  • GRANDIS, J. R., DRENNING, S. D., ZENG, Q., WATKINS, S. C., MELHEM, M. F., ENDO, S., JOHNSON, D. E., HUANG, L., HE, Y. & KIM, J. D. 2000. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A, 97, 4227-32.
  • First- and Second-Generation EGFRTKI Are All Replaced to Osimertinib in Chemo-Naive EGFR MutationPositive Non-Small Cell Lung Cancer ?
    20 . [2019]
  • Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
    25 , 4798-811 [2006]
  • Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions : immunocytochemical and quantitative image analyses
    150 , 15-23 . [1997]
  • Establishment of a human non-small cell lung cancer cell line resistant to gefitinib .
    116 , 36-44 [2005]
  • ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinibsensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A, 102, 3788-93.
  • Epidermal growth factor receptor targeting in cancer : a review of trends and strategies
    34 , 8690-707 [2013]
  • Endoplasmic Reticulum Stress and Associated ROS
    17 , 327 [2016]
  • Economic Burden of Cancer in Korea during 2000-2010
    47 , 387-98 . [2015]
  • ENGELMAN, J. A., ZEJNULLAHU, K., MITSUDOMI, T., SONG, Y., HYLAND, C., PARK, J. O., LINDEMAN, N., GALE, C. M., ZHAO, X., CHRISTENSEN, J., KOSAKA, T., HOLMES, A. J., ROGERS, A. M., CAPPUZZO, F., MOK, T., LEE, C., JOHNSON, B. E., CANTLEY, L. C. & JANNE, P. A. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039-43.
  • E. S. & COMMUNITY OF POPULATION-BASED REGIONAL CANCER , R. 2018 . Cancer Statistics in Korea : Incidence , Mortality , Survival , and Prevalence in 2015
    50 , 303-316 .
  • E. & VANDE WOUDE , G. F. 2003 . Met , metastasis , motility and more
    4 , 915- 25 .
  • Differential roles of trans-phosphorylated EGFR , HER2 , HER3 , and RET as heterodimerisation partners of MET in lung cancer with MET amplification
    105 , 807-13 [2011]
  • DAY, T. A., DAVIS, B. K., GILLESPIE, M. B., JOE, J. K., KIBBEY, M., MARTINHARRIS, B., NEVILLE, B., RICHARDSON, M. S., ROSENZWEIG, S., SHARMA, A. K., SMITH, M. M., STEWART, S. & STUART, R. K. 2003. Oral cancer treatment. Curr Treat Options Oncol, 4, 27-41.
  • D. EEK , R. , HORAI , T. , NODA , K. , TAKATA , I. , SMIT , E. ,
    , A. , FEYEREISLOVA
  • Cytometric assessment of DNA damage in relation to cell cycle phase and apoptosis
    38 , 223-43 [2005]
  • Cyclooxygenase ( COX ) -2 as a potent molecular target for prevention and therapy of oral cancer
    44 , 57-65 [2008]
  • Cyclo-oxygenase-2 expression in oral squamous cell carcinoma
    10 , 1024-9 [2014]
  • Crosstalk between apoptosis , necrosis and autophagy
    1833 , 3448-3459 [2013]
  • Clinical update on head and neck cancer : molecular biology and ongoing challenges
    10 , 540 . [2019]
  • Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis
    94 , 491-501 [1998]
  • Chemopreventive effects of licorice and its components
    1 , 60-71 [2015]
  • Cell cycle and apoptosis
    2 , 291-9 . [2000]
  • Cardioprotection provided by Echinatin against ischemia/reperfusion in isolated rat hearts
    16 , 119 . [2016]
  • Cancer drug resistance : an evolving paradigm
    13 , 714-26 [2013]
  • CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells
    279 , 45495-45502 [2004]
  • CHANG, A., PARIKH, P., THONGPRASERT, S., TAN, E. H., PERNG, R. P., GANZON, D., YANG, C. H., TSAO, C. J., WATKINS, C., BOTWOOD, N. & THATCHER, N. 2006. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol, 1, 847-55.
  • C. P. 1998 . Annexin V-affinity assay : a review on an apoptosis detection system based on phosphatidylserine exposure
    31 , 1-9 .
  • C. H. 2014 . SB365 , Pulsatilla saponin D , suppresses the growth of gefitinib-resistant NSCLC cells with Met amplification
    32 , 2612-8 .
  • BEAN, J., BRENNAN, C., SHIH, J.-Y., RIELY, G., VIALE, A., WANG, L., CHITALE, D., MOTOI, N., SZOKE, J. & BRODERICK, S. 2007. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A, 104, 20932-20937.
  • BCL-2 family isoforms in apoptosis and cancer
    10 , 177 [2019]
  • B. P. & RUPASINGHE , H. P. V. 2018 . Kinase-targeted cancer therapies : progress , challenges and future directions
    17 , 48 .
  • Astaxanthin inhibits JAK/STAT-3 signaling to abrogate cell proliferation , invasion and angiogenesis in a hamster model of oral cancer
    9 , e109114 [2014]
  • Apoptosis and molecular targeting therapy in cancer ’
    150845 [2014]
  • Apoptosis : a review of programmed cell death
    35 , 495-516 [2007]
  • Anticancer drug discovery from Chinese medicinal herbs
    13 , 35 [2018]
  • Anticancer Activity of Natural Compounds from Plant and Marine Environment
    19 [2018]
  • Anti-cancer Effects of Polyphenolic Compounds in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer
    13 , 595-599 .
  • Anti-apoptosis and cell survival : a review
    [2011]
  • Advances in cancer therapy with plant based natural products
    8 , 1467-86 [2001]
  • Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall-cell lung cancers dependent on the epidermal growth factor receptor pathway
    10 , 281-9 [2009]
  • AZD1480 : a phase I study of a novel JAK2 inhibitor in solid tumors
    18 , 819-20 . [2013]
  • A. Nonsmall cell lung cancer : epidemiology , risk factors , treatment , and survivorship
  • A. , JANNE , P. A. , MERMEL , C. , PEARLBERG , J. , MUKOHARA , T. , FLEET , C. , CICHOWSKI , K. , JOHNSON
    [2005]
  • A review on oral cancer biomarkers : Understanding the past and learning from the present .
    12 , 486-92 [2016]
  • A fate worse than death : apoptosis as an oncogenic process
    16 , 539 . [2016]
  • A decade of caspases
    22 , 8543-67 . [2003]
  • A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
    387 , 505-21 [2014]
  • A Systematic Review of the Anticancer Properties of Compounds Isolated from Licorice ( Gancao )
    81 , 1670-87 . [2015]
  • A Review : Phytochemicals Targeting JAK/STAT Signaling and IDO Expression in Cancer
    29 , 805-17 . [2015]
  • 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer
    39 , 380- 5 [2003]
  • 1997. p27Kip1 overexpression causes apoptotic death of mammalian cells
    15 , 2991-7
  • , WENG , S. , WANG , L. , YE , M. ,
    CHEN , H. ,
  • , SEKIDO , Y. , UENAKA , T. YANO , S. 2012 .Combined therapy with mutant-selective EGFR
    inhibitor for overcoming erlotinib
  • , MITCHELL , J. , GYGI , S.
    D. & COMB
  • , M. 2005 . High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of
    . Cancer Res ,
  • , LIU , S. Y. , DONG , Z. Y. , GAO , H. F. , ZHOU , Q. , ZHONG , W. Z. , XU
    & WU , Y.
  • , L. 2017 . Biological Effect of LicochalconeC on the Regulation of PI3K/Akt/eNOS and NF-kappaB/iNOS/NO Signaling Pathways in H9c2Cells in
    J
  • , H. , FUJII , Y. , ECK , M. J. , SELLERS
    , JOHNSON , B.
  • , G. I. , SHIMAMURA , T. WONG , K. K. 2012 .Combined EGFR/MET or EGFR/HSP90 inhibition is effective
    lung cancers codriven by
  • , G. B . 2015 .Curcumin suppresses invasiveness and vasculogenic mimicry of squamousCellCarcinoma of the larynx through
    . Am J
  • , G. &CICCIU , M. 2019 . Molecular Biomarkers Related to OralCarcinoma :
    Literature